Navigation Links
PURE Bioscience Granted US Patent on SDC for Food Treatment
Date:10/30/2008

New Patent Protects PURE in Emerging Food Processing Market for SDC

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced that the United States Patent and Trademark Office issued patent number 7,435,438, which covers PURE's process for treating consumable food products with silver dihydrogen citrate (SDC) to reduce or eliminate microbial contamination. The new patent expands the scope of protection of PURE's core technology patent, US Patent 6,197,814, covering the composition and method of making of PURE's silver dihydrogen citrate (SDC) antimicrobial.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

Michael L. Krall, President and CEO of PURE Bioscience, stated, "Food safety is an ongoing public health concern in the United States, and this new patent provides strategic protection for PURE as we explore applications for SDC in the food processing market with industry leading companies. We continue to build our patent portfolio, both in the US and abroad, to fully protect the numerous potential uses for SDC."

PURE Bioscience's EPA-registered SDC-based disinfectant is a powerful weapon against food borne pathogens, including E. coli, Campylobacter, Listeria, Norovirus and Salmonella. According to information published by the CDC in 2005, known pathogens causing food borne illness account for approximately 14 million illnesses, 60,000 hospitalizations and 1,800 deaths annually in the US.

PURE has four previously granted US patents related to the SDC technology: US Patent 6,197,814 (2001) for the SDC disinfectant and method of its making, Patent 6,583,176 (2003) covering the combination of SDC and alcohol as a disinfectant, Patent 6,890,953 (2005) covering a process for treating water with SDC and Patent 7,261,905 (2007) covering PURE's process of manufacturing complexes of electrolytically generated stabilized ionic silver with various organic acids. PURE also has numerous other patent applications pending in the US, including, among others, coverage of SDC in medical, personal care and preservative applications, the anhydrous - or crystalline - form of SDC, and SDC in combination with traditional chemical disinfectants. In addition, patents have issued or are pending for PURE's SDC technology in approximately 70 countries.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PURE Bioscience Investor Contact:

Paul G. Henning, Vice President

Cameron Associates

(212) 554-5462

paul@cameronassoc.com

PURE Press Contact:

Suzanne Matick

Gutenberg Communications

(831) 479-1888

Suzanne@gutenbergpr.com


'/>"/>
SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer
2. Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo
3. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
6. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
7. Ardea Biosciences Announces Upcoming Corporate Meetings
8. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
9. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
10. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
11. Numira Biosciences Names New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has ... go for gold in Rio. Under the care of Maximized Living doctors at ... In an unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial ... for Graduate Medical Education (ACGME) that it has received accreditation for its residency ... of three residency programs that Memorial is currently pursuing, including Pediatrics and Internal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment of ... invited to be a featured speaker at the Texas Society of the American College ... , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will speak ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
Breaking Medicine Technology: